Vanguard Capital Management
PRCT icon

Vanguard Capital Management’s Procept Biorobotics PRCT Stock Holding History

Vanguard Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6M Buy
2,460,802
+61,735
+3% +$1.55M ﹤0.01% 1883
2026
Q1 		$60M Buy
+2,399,067
New +$67.6M ﹤0.01% 1761

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management's PRCT Position: Q2 2026 in Review

Vanguard Capital Management increased its Procept Biorobotics (PRCT) stake by 2.6% in Q2 2026, buying an estimated $1.55M and bringing the position to 2,460,802 shares worth $55.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

Vanguard Capital Management first reported a position in PRCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $60M in Q1 2026. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Vanguard Capital Management held 2,460,802 shares of Procept Biorobotics worth $55.6M as of Q2 2026.
  • Vanguard Capital Management bought 61,735 Procept Biorobotics shares in Q2 2026, an estimated $1.55M.
  • Procept Biorobotics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1883 holding.
  • Vanguard Capital Management first reported a position in Procept Biorobotics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Procept Biorobotics position peaked at $60M in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.